Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

The European Union's drug regulator on Friday recommended conditional authorisation of Madrigal Pharmaceuticals' Rezdiffra, ...

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.

The USDA considers vaccinating poultry for bird flu, while the EU supports Madrigal's liver drug Rezdiffra. Meanwhile, the ...

Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.

If approved in Europe, Rezdiffra would hold the same indication. Madrigal secured accelerated approval from the US FDA for Rezdiffra in March 2024, making it the first MASH treatment in the US market.

Conshohocken, Pennsylvania Monday, June 23, 2025, 13:30 Hrs [IST] ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

The USDA considers vaccinating poultry against bird flu, aiming to evaluate the impact on exports; nearly 175 million poultry have been culled. The EU supports a conditional OK for Madrigal’s liver ...